11 active not recruiting, 10 completed. 14 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Active not recruiting 8, Completed 6 |
| Phase 2 | 12 | Active not recruiting 6, Completed 6 |
Follow berzosertib: new trials by email Literature Review of berzosertib trials Research Report on berzosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208) [14C]Berzosertib, Berzosertib, Topotecan - Advanced Solid Tumor | Phase 1 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 6 | 2022-02-15 | 2024-11-22 |
| A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors Berzosertib, Sacituzumab Govitecan - HRD Cancer, SCLC | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 35 | 2021-09-20 | 2026-07-21 |
| Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers Lurbinectedin, Berzosertib - SCLC, Small Cell Cancer | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 37 | 2021-06-01 | 2026-03-17 |
| Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Berzosertib, Biospecimen Collection, Carboplatin - Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 12 | 2021-04-14 | 2026-09-21 |
| Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) Berzosertib, Topotecan - Small-cell Lung Cancer | Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 76 | 2021-03-29 | 2024-09-26 |
| Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer Berzosertib, Computed Tomography Assisted Biopsy, Endoscopic Biopsy - Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2020-11-16 | 2026-10-20 |
| Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer Berzosertib, Biospecimen Collection, Quality-of-Life Assessment - Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2020-09-24 | 2026-07-31 |
| Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors Avelumab, Berzosertib - Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 23 | 2020-03-17 | 2026-06-11 |
| Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs Berzosertib, Biopsy Procedure, Biospecimen Collection - Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 104 | 2019-12-30 | 2026-07-31 |
| M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Berzosertib, Carboplatin, Docetaxel - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 73 | 2019-05-29 | 2026-10-09 |
| M6620 (VX-970) in Selected Solid Tumors M6620 - Solid Tumor, Leiomyosarcoma | Phase 2 | Completed | Massachusetts General Hospital | 30 | 2019-01-08 | 2023-07-07 |
| ATRi Transition Rollover Study Berzosertib - Advanced Stage Solid Tumors | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 1 | 2018-01-10 | 2024-11-29 |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors Veliparib + VX-970 + Cisplatin - Neoplasms | Phase 1 | Completed | National Cancer Institute (NCI) | 53 | 2017-08-09 | 2022-02-08 |
| Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors Berzosertib, Quality-of-Life Assessment, Therapeutic Conventional Surgery - Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 15 | 2017-05-22 | 2026-10-14 |
| Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Berzosertib, Carboplatin, Gemcitabine Hydrochloride - Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2017-05-16 | 2026-07-31 |
| Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer Berzosertib, Cisplatin, Computed Tomography - Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 43 | 2017-04-17 | 2026-07-31 |
| Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer Berzosertib, Cisplatin, Gemcitabine Hydrochloride - Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 87 | 2017-01-31 | 2025-03-03 |
| Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Berzosertib, Gemcitabine, Gemcitabine Hydrochloride - Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 70 | 2016-08-25 | 2026-09-09 |
| M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Berzosertib, Biopsy Specimen, Biospecimen Collection - Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 66 | 2016-07-22 | 2026-09-25 |
| Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers Topotecan, VX-970 (M6620) - Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 62 | 2015-07-30 | 2025-04-13 |
Showing 20 of 21. Sign in to see all of them.
Small Cell Lung Carcinoma (6) · Hereditary Sensory and Autonomic Neuropathies (3) · Lung Neoplasms (3) · Ovarian Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Fallopian Tube Neoplasms (2) · Neoplasm Metastasis (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Neuroendocrine (1) · Colorectal Neoplasms (1) · Leiomyosarcoma (1) · Neoplasms (1) · Osteosarcoma (1) · Pancreatic Neoplasms (1)
National Cancer Institute (NCI) (15) · EMD Serono Research & Development Institute, Inc. (2) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · Merck KGaA, Darmstadt, Germany (1)
United States (19) · United Kingdom (2) · Belgium (1) · China (1) · France (1) · Hungary (1) · Italy (1) · Japan (1) · Spain (1)
Anish Thomas, M.D. (3) · Liza C Villaruz (2) · Alice P Chen, M.D. (1) · Andrea E Wahner Hendrickson (1) · Arun Rajan (1) · Atish D Choudhury (1) · Gregory M Cote, MD, PhD (1) · Jordan D Berlin (1) · Panagiotis A Konstantinopoulos (1) · Pranshu Mohindra (1) · Robert W Mutter (1) · Sumanta K Pal (1) · Taofeek K Owonikoko (1) · Timothy A Yap (1)
PMID 42820295, PMID 29252124, PMID 31401903, PMID 32553118, PMID 33145616, PMID 34040174, PMID 34040175, PMID 34436521, PMID 34904813, PMID 37491889, PMID 37824137, PMID 38635934, PMID 40437704, PMID 40669022, PMID 41206673, PMID 41335461
UM1CA186690 (5), UM1CA186709 (4), UM1CA186686 (3), UM1CA186689 (2), UM1CA186691 (2), UM1CA186717 (2), 2017 (1), N01CM00038 (1), N01CM00099 (1), N01CM00100 (1), P30CA015083 (1), UM1CA186644 (1), UM1CA186704 (1), ZIABC011078 (1)